The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 334:1479-1480 May 30, 1996 Number 22
NextNext

Lack of Sustained Efficacy of Interferon in Patients with Chronic Hepatitis C

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: The hepatitis C virus (HCV) has been shown to cause progressive and chronic liver damage.1 Interferon therapy apparently eradicates HCV in 20 to 30 percent of patients, but the follow-up in published studies is generally short (6 to 18 months) and never exceeds 3 to 5 years.2,3,4

We followed for 92 to 99 months (mean, 93) 13 patients (9 men and 4 women; mean age, 35 years; range, 21 to 54) who had received 3 million units of recombinant interferon alfa-2a (Roferon r-A, Roche) or interferon alfa-2b (Intron A, Schering-Plough) three times per week for 6 months . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.